Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2299-5684

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance ; volume:72 ; number:4 ; day:14 ; month:7 ; year:2020 ; pages:799-813 ; date:8.2020
Pharmacological reports ; 72, Heft 4 (14.7.2020), 799-813, 8.2020

Creator: Maity, Swastika
Pai, K. Sreedhara Ranganath
Nayak, Yogendra

Contributor: SpringerLink (Online service)

DOI: 10.1007/s43440-020-00131-0

URN: urn:nbn:de:101:1-2020092311441318130332

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Maity, Swastika
Pai, K. Sreedhara Ranganath
Nayak, Yogendra
SpringerLink (Online service)

Other Objects (12)

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Emerging strategies to overcome resistance to third-generation EGFR inhibitors

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients

Related objects

Reset password